Paragon 28, Inc. - FNA STOCK NEWS

Paragon 28, Inc. (NYSE: FNA) has completed the sale of an additional 975,000 shares following an underwritten public offering of 6,500,000 shares at $17.00 per share. The total proceeds from the offering approximated $73.3 million, with 562,500 shares sold by Paragon and 412,500 shares by selling securityholders. The funds will primarily support working capital, capital expenditures, and other corporate purposes, potentially including acquisitions. The public offering was conducted under an SEC registration statement filed in November 2022.

Paragon 28, Inc. (NYSE: FNA), a leader in the foot and ankle orthopedic market, will release its financial results for Q4 and FY 2022 after market close on March 2, 2023. A conference call will follow at 4:30 p.m. ET, available for investors by dialing (844-200-6205) domestically and (929-526-1599) internationally, with conference ID 798665. The call will also be accessible via webcast on the company's investor website. Established in Englewood, Colo., Paragon 28 focuses on innovative orthopedic solutions aimed at improving patient outcomes in foot and ankle conditions.

Paragon 28, Inc. (NYSE: FNA) announced a public offering of 6,500,000 shares of its common stock, priced at $17.00 per share, aiming to raise approximately $63.8 million. The offering involves 3,750,000 shares from Paragon and 2,750,000 shares from selling securityholders, with underwriters granted a 30-day option for an additional 975,000 shares. Proceeds will support working capital, capital expenditures, and potential investments in complementary products, although no agreements are currently in place. The offering is set to close on January 30, 2023.

Paragon 28, Inc. (NYSE: FNA) has announced a proposed underwritten public offering of 6,500,000 shares of its common stock, with 3,750,000 shares from Paragon and 2,750,000 shares from selling securityholders. Additionally, underwriters may purchase 975,000 shares under a 30-day option. Proceeds will primarily support working capital and corporate needs, with possibilities for product investments. However, Paragon will not benefit from the sale of shares by selling securityholders. BofA Securities and Piper Sandler & Co. lead the offering, which is subject to market conditions.

Paragon 28, Inc. (NYSE: FNA) has announced its preliminary unaudited revenue for Q4 and the full year of 2022. Q4 revenue is projected between $51.2 million and $51.5 million, marking a growth of approximately 20% year-over-year, despite foreign currency challenges impacting growth by 1.6 percentage points. For the full year, net revenue is expected to be between $181.0 million and $181.3 million, reflecting a growth of about 23.0% compared to 2021. The company plans to release its 2023 financial guidance later in the quarter.

Paragon 28, Inc. (NYSE: FNA), a leader in the medical device sector focusing on the foot and ankle orthopedic market, will have CEO Albert DaCosta and CFO Steve Deitsch participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference. This event is scheduled for Thursday, December 1, 2022, at 8:30 a.m. Eastern Time. A live webcast and archived recording will be accessible on the company's investor relations website.

Paragon 28 is committed to improving patient outcomes through innovative orthopedic solutions.

Paragon 28, Inc. (NYSE: FNA) reported a record net revenue of $46.0 million for Q3 2022, marking a 28% increase from the previous year. U.S. revenue reached $40.0 million, up 25%, driven by improved sales productivity and new product launches. International revenue also set a record at $6.0 million, growing 52%. Despite foreign currency headwinds impacting revenue by $0.8 million, the company raised its 2022 net revenue guidance to $179.5 million, reflecting a 22% growth. However, net loss expanded to $9.7 million, contributing to a negative adjusted EBITDA of $2.7 million.

Paragon 28, Inc. (NYSE: FNA), a leading medical device company focused on foot and ankle orthopedics, will release its third-quarter 2022 financial results on November 10, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results. Investors can participate by dialing (844-200-6205) or (929-526-1599) internationally, using conference ID: 703484. The call will be available for replay for 90 days on the company’s website.

Paragon 28, Inc. (NYSE: FNA), a leading medical device company focused on foot and ankle orthopedics, announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference. The company's Chairman and CEO, Albert DaCosta, along with CFO Steve Deitsch, will present a fireside chat on September 13, 2022, at 3:30 p.m. ET. A live webcast will be accessible through the investor relations section of their website at ir.paragon28.com.